crlx 280.jpg
DSC_2399.jpg
xqo1.013_B8-top_grt-06_07-12-2011.jpg
HA_grau2_bearbeitet-1.png
xph3.002_apo_09032012_9_1.jpg
iStock_000011597770XLarge-organge.jpg
crlx 280.jpg

PRIME PROTEIN


Ultra pure proteins - customized for your specific needs

 

SCROLL DOWN

PRIME PROTEIN


Ultra pure proteins - customized for your specific needs

 

With our proprietary bi-turbo vector system, we express target proteins in parallel in E.coli and insect cells from the same plasmid construct. These vectors are available with different baculovirus promotors for optimal timing of recombinant protein expression. Optimized virus DNA backbones, developed by us, allow convenient co-expression of additional factors to enhance yield and homogeneity of recombinant proteins. Our highly parallelized expression systems are optimized to significantly increase protein recovery while concomitantly reducing time and costs.

In addition, CRELUX offers recombinant proteins from mammalian cell culture, e.g. HEK cells, and proteins specifically labelled for NMR experiments.

All our customized recombinant proteins undergo stringent quality control and offer an excellent price-performance ratio.

Contact us for a detailed PRIME PROTEIN proposal that meets your specific needs.

DSC_2399.jpg

INTRACT


Biophysical Assays and Screening

Fragment Screening

 

Alpha Screen   

Enzyme Activity  

Fluorescence Cross-Correlation Spectroscopy   

Fluorescence Polarization Assays  

Kinetic Assays

LC-MS Screening

Microscale Thermophoresis

Nano DSF

NMR Screening

SPR

SwitchSENSE

INTRACT


Biophysical Assays and Screening

Fragment Screening

 

Alpha Screen   

Enzyme Activity  

Fluorescence Cross-Correlation Spectroscopy   

Fluorescence Polarization Assays  

Kinetic Assays

LC-MS Screening

Microscale Thermophoresis

Nano DSF

NMR Screening

SPR

SwitchSENSE

Whether you are looking for reliable biophysical analytics of your protein or whether you require an innovative compound and fragment screening platform – INTRACT provides all the services you need. It includes measurements of enzymatic activities, Kon/off binding kinetics, KD analyses and stability determination of proteins.

 The INTRACT biophysical analytics and screening platform is made of a versatile series of orthogonal assay technologies for hit validation and includes: SPR, DSF/nanoDSF, microscale thermophoresis (MST), AlphaScreen, NMR, fluorescence cross correlation spectroscopy (FCCS) and many more.

Our robotics-enhanced screening platform provides efficient, cutting-edge technologies for protein biophysical services and for the analysis and validation of compounds. Thus, INTRACT enables highly accurate and sensitive measurements under close-to-native conditions to reliably guide the optimization of your compounds.

 

Contact us for a detailed INTRACT proposal that meets your specific needs.

xqo1.013_B8-top_grt-06_07-12-2011.jpg

XPRESS


Choose from our list of 170 pre-established targets

and receive the complex structures usually within less than eight weeks

 

Tyrosine Kinases ABL ALK AXL1 C-FMS C-KIT DYRK1A DYRK2 EGFR EGFR G719S EGFR L858R EGFR T790M EGFR T790M/L858R EPHA4 EPHB4 FAK FES FGFR1 FGFR2 FGFR3 FGFR4 FLT3 FYNB HCK IGF1-R JAK1 JAK2 JAK3 LCK LYN MER (AXL2) MET RET SRC SYK TRKA TRKB TYK2

Serine/Threonine Kinases ACVR1 ACVR2A ACVR2B AKT1 AKT2 AMPK ALK1 ALK4 ALK5 ASK1 AurA BRAF CAMK2G CDK2 CDK7 CDK8/CycC CDK9/CycT1 CDK12/CycK CHK1 CK1d CK1g DAPK3 ERK2 ERK3/MAPK6 GSK3b HASPIN IRAK4 IRE1 JNK1 JNK2 JNK3 LIMK1 MAPK1 MAPK13 MAPK2 MAPK3 MAP3K7 MEK-1 MKNK2 MPS1 MSK-1 NEK2 P38 PAK1 PAK4 PDK1 PIM1 PIM2 PKA PKCi PKCe PLK1 PLK4 PKR ROCK2 RSK1 RSK2 TAB1/TAK1 TNIK TGFBR1 TGFBR2

Epigenetic Targets BRD2 - BET1 BRD2 - BET2 BRD3 - BET1 BRD3 - BET2 BRD4 - BET1 BRD4 - BET2 BRD9 - BET BRDT - BET1 BRPF1 BRPF3 CARM1 CREBBP EHMT1 HDAC2 HDAC3/NCOR HDAC4 HDAC7 HDAC8 JMJD2A JMJD2C JMJD2D KDMA1 MYST1 PARP1 PARP12 PARP14 PARP15 PARP3 PHF8 SIRT2 SIRT5 TAF1 TANKYRASE1

Nuclear Receptors ERa GR MCR PPARa PPARd PPARg PR RORa RORb RORgT RXRb/LXRb

Metabolic Targets IDH1 IDH1 R132H IDH2 GLS1 LDHA NNMAT PGK1 PHGDH PKM2 PSAT1 Rare Disease MCAD PAH Proteases BACE1 Cathepsin K Cathepsin S CMA1/Chymase Proteasome

Other BAK1 BCL2A1 CYP-2D6 CYP-3A4 DHODH DJ-1 HSP70 HSP70-BAG1 HSP90 HSP90-CDC37MCL1 NLRP1 MCL1 PDE7A PDE9A PI3Kgamma PI3Kdelta PTP-1B PTPN11 (SHP2) PTPN22 USP7

Fab Fc Antibodies

XPRESS


Choose from our list of 170 pre-established targets

and receive the complex structures usually within less than eight weeks

 

Tyrosine Kinases ABL ALK AXL1 C-FMS C-KIT DYRK1A DYRK2 EGFR EGFR G719S EGFR L858R EGFR T790M EGFR T790M/L858R EPHA4 EPHB4 FAK FES FGFR1 FGFR2 FGFR3 FGFR4 FLT3 FYNB HCK IGF1-R JAK1 JAK2 JAK3 LCK LYN MER (AXL2) MET RET SRC SYK TRKA TRKB TYK2

Serine/Threonine Kinases ACVR1 ACVR2A ACVR2B AKT1 AKT2 AMPK ALK1 ALK4 ALK5 ASK1 AurA BRAF CAMK2G CDK2 CDK7 CDK8/CycC CDK9/CycT1 CDK12/CycK CHK1 CK1d CK1g DAPK3 ERK2 ERK3/MAPK6 GSK3b HASPIN IRAK4 IRE1 JNK1 JNK2 JNK3 LIMK1 MAPK1 MAPK13 MAPK2 MAPK3 MAP3K7 MEK-1 MKNK2 MPS1 MSK-1 NEK2 P38 PAK1 PAK4 PDK1 PIM1 PIM2 PKA PKCi PKCe PLK1 PLK4 PKR ROCK2 RSK1 RSK2 TAB1/TAK1 TNIK TGFBR1 TGFBR2

Epigenetic Targets BRD2 - BET1 BRD2 - BET2 BRD3 - BET1 BRD3 - BET2 BRD4 - BET1 BRD4 - BET2 BRD9 - BET BRDT - BET1 BRPF1 BRPF3 CARM1 CREBBP EHMT1 HDAC2 HDAC3/NCOR HDAC4 HDAC7 HDAC8 JMJD2A JMJD2C JMJD2D KDMA1 MYST1 PARP1 PARP12 PARP14 PARP15 PARP3 PHF8 SIRT2 SIRT5 TAF1 TANKYRASE1

Nuclear Receptors ERa GR MCR PPARa PPARd PPARg PR RORa RORb RORgT RXRb/LXRb

Metabolic Targets IDH1 IDH1 R132H IDH2 GLS1 LDHA NNMAT PGK1 PHGDH PKM2 PSAT1 Rare Disease MCAD PAH Proteases BACE1 Cathepsin K Cathepsin S CMA1/Chymase Proteasome

Other BAK1 BCL2A1 CYP-2D6 CYP-3A4 DHODH DJ-1 HSP70 HSP70-BAG1 HSP90 HSP90-CDC37MCL1 NLRP1 MCL1 PDE7A PDE9A PI3Kgamma PI3Kdelta PTP-1B PTPN11 (SHP2) PTPN22 USP7

Fab Fc Antibodies

Our XPRESS service provides fast, reliable and affordable access to pre-established co-crystal structures. Send us your compounds, and you will receive the complex structures, typically within eight weeks or less. To achieve this, CRELUX has optimized expression, purification and crystallization conditions for XPRESS targets. Our XPRESS portfolio represents one of the largest collections of human therapeutic targets worldwide – and it is constantly growing.

 Take advantage of the benefits of our special expertise in crystallization of epigenetic targets and kinases. In addition, our portfolio is complemented by many other targets from a variety of classes, including, for example, membrane proteins, nuclear receptors and antibodies. We are constantly adding new XPRESS proteins to our portfolio, and a large number of additional established targets are also available under XPRESS conditions that do not show up on this list.

Please contact us for information regarding your specific target and request a detailed XPRESS proposal that matches your specific needs.

HA_grau2_bearbeitet-1.png

XPEDITE


Quick access to published targets and their disease relevant variants

XPEDITE


Quick access to published targets and their disease relevant variants

XPEDITE grants you reliable and quick access to complex structures of published targets with your proprietary compounds. The XPEDITE project structure is the same as for our XPRESS portfolio only with the upfront addition of a protein production phase. XPEDITE projects also include the work on disease relevant mutations of established targets and the optimization of published but low quality structures.

 

With the dawn of personalized medicine and the occurrence of inhibitor resistant variants in cancer patients the investigation of disease relevant mutations becomes more and more important. XPEDITE grants you access to complex structures of mutated target proteins and enables our clients to investigate the molecular mode of action for their drug candidates.

 

xph3.002_apo_09032012_9_1.jpg

XPERT


De novo and structures of challenging targets

 

XPERT


De novo and structures of challenging targets

 

You are looking for professional and skilled solutions for customized protein production and de novo structure analysis projects for your target of choice? Our XPERT program can precisely meet your requirements. Our team of highly experienced experts will design and implement a robust and reliable process to enable customized structural analysis of even the most challenging targets. Benefit from our many years of experience and broad expertise in protein science, resulting in our successful structure solving of more than 200 different target proteins, combined with our flexible, fair and success-based payment plans. We are firmly committed to providing you with exactly what you need, on time and within budget. To facilitate a high level of transparency, we provide you with immediate status reports, face-to-face meetings or telephone conferences as requested. CRELUX does not lay claim to any intellectual property on fragments or structures. Final and intermediate project data are immediately transferred to the customer to enable control of the results we provide.

iStock_000011597770XLarge-organge.jpg

Integrated drug discovery


Seamless from hit finding to lead optimization



 

 

 

Integrated drug discovery


Seamless from hit finding to lead optimization



 

 

 

You are looking for integrated discovery solutions out of one hand?

CRELUX performs hit identification, confirmation, and validation. Hit-to-lead optimization is performed by our parent company, WuXi AppTec.

Fast and cost-efficient hit finding is based on a combination of unique computer-based (vHTS) or fragment based screening with sophisticated wet-lab discovery technologies.

For more information, please contact us.